Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
Latest News

Shilpa Medicare receives EIR from USFDA

Shilpa Medicare has received establishment inspection report (EIR), from United States Food and Drug Administration (USFDA).

The company has received of EIR for both API manufacturing facilities located at Raichur, Karnataka, from USFDA. This inspection was carried out between 16 to 19 January, 2018 and the inspection has now been closed by USFDA.

Read EquityPandit’s Technical Analysis of Nifty Pharma

Get Daily Prediction & Stocks Tips On Your Mobile